A New Combination Proves Itself in Treatment for Type 2 Diabetes

Poll

Question 2. The rationale for combination therapy with SGLT2 inhibitor and a DPP-4 inhibitor is based on:

A. Increased bioavailability of both drugs when administered together.
B. Less glucose production in the presence of a DPP-4 inhibitor in response to the glucosuria produced by SGLT2 inhibition
C. Increased affinity of the SGLT2 inhibitor to its target in the renal tubule in the presence of a DPP-4 inhibitor.
D. None of the above
Related Videos
Erin Michos, MD | Credit: Johns Hopkins University
Natalie McCormick, PhD | Credit: American College of Rheumatology
Medha Munshi, MD, (Courtesy: Harvard Health)
David Maahs, MD, PhD
Related Content

SGLT2 Inhibitors Did Not Increase Fracture Risk in Postmenopausal Patients with T2D

September 29th 2023

Untapped Potentials: Exploring Overlooked Therapies for Type 2 Diabetes

September 29th 2023

Pharmacist-Led Interventions Can Improve HbA1c in Underserved Communities

September 29th 2023

Diabetes Dialogue: Establishing Time in Range as a Primary Glucose Metric

July 6th 2023

Study Identifies Successful Strategies for Improving Diabetes Care Delivery

September 26th 2023

Tirzepatide Bests Semaglutide For A1c, Weight Loss in Indirect Comparison of Clinical Trial Data

September 25th 2023

SGLT2 Inhibitors Did Not Increase Fracture Risk in Postmenopausal Patients with T2D

September 29th 2023

Untapped Potentials: Exploring Overlooked Therapies for Type 2 Diabetes

September 29th 2023

Pharmacist-Led Interventions Can Improve HbA1c in Underserved Communities

September 29th 2023

Diabetes Dialogue: Establishing Time in Range as a Primary Glucose Metric

July 6th 2023

Study Identifies Successful Strategies for Improving Diabetes Care Delivery

September 26th 2023

Tirzepatide Bests Semaglutide For A1c, Weight Loss in Indirect Comparison of Clinical Trial Data

September 25th 2023

SGLT2 Inhibitors Did Not Increase Fracture Risk in Postmenopausal Patients with T2D

September 29th 2023

Untapped Potentials: Exploring Overlooked Therapies for Type 2 Diabetes

September 29th 2023

Pharmacist-Led Interventions Can Improve HbA1c in Underserved Communities

September 29th 2023

Diabetes Dialogue: Establishing Time in Range as a Primary Glucose Metric

July 6th 2023

Study Identifies Successful Strategies for Improving Diabetes Care Delivery

September 26th 2023

Tirzepatide Bests Semaglutide For A1c, Weight Loss in Indirect Comparison of Clinical Trial Data

September 25th 2023
© 2023 MJH Life Sciences

All rights reserved.